Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Addiction. 2015 Jul 21;110(10):1667–1675. doi: 10.1111/add.12978

Table 2. Smoking behavior and biomarkers of exposure while smoking reduced nicotine cigarettes means.

Characteristic Baseline (usual) 6 Months (1 mg) 12 Months (1mg) 18 Months 24 Months Significant Interactions
Control (n=55) Control (n=50) Control (n=48) Control (n=40) Control (n=38)
Research (n=80) Research (n=53) Research (n=37) Research (n=32) Research (n=30)
Cigarettes per day 20 (18, 22) 22 (19, 25) 21 (18, 23) 17 (14, 20) a,b,c 16 (14, 19) a,b,c 6M v. BL, 24M v. BL
23 (21, 25) 20 (17, 23) 22 (18, 25) 17 (14, 21) a,b,c 13 (9, 17) a,c

Plasma cotinine ng/mL 268 (233, 302) 239 (202, 278) a 267 (223, 310) 238 (192, 284) 209 (174, 244) a,c 6M v. BL, 12M v. BL
250 (222, 277) 113 (81, 145) a 149 (110, 188) a 210 (170, 250) b,c 173 (135, 211) c 18M v. 6M, 24M v. 6M
18M v. 12 M, 24M v. 12M

Expired CO (ppm) 22 (19, 2) 20 (17, 23) 23 (20, 26) 20 (18, 24) 19 (15, 22) NS
25 (22, 28) 23 (19, 26) 23 (19, 27) 22 (17, 27) 20 (15, 24)

Urine (pmol/mg creatinine)
 Total NNAL* 1.0 (0.7, 1.3) 0.9 (0.6, 1.2) 0.8 (0.7, 0.9) 0.6 (0.4, 0.7) 6M v. BL
1.4 (1.1, 1.7) 0.8 (0.5, 1.1)a 0.8 (0.7, 0.9) a 0.7 (0.6, .09)

 Sum of phenanthrenes* 3.5 (2.8, 4.4) 4.0 (3.3, 4.7) 4.0 (1.1, 7.0) NS
4.0 (3.3, 4.7) 3.9 (3.1, 4.8) 3.8 (2.0, 6.1)

 2-naphthol* 97 (73, 129) 112 (92, 136) 105 (102, 108) NS
161 (123, 210) 137 (107, 174) 115 (113, 117)

 2-hydroxyfluorene* 13 (10, 17) 15 (12, 18) 14 (12, 16) NS
17 (14, 22) 17 (13, 23) 16 (14, 18)

 1-hydroxypyrene* 1.1 (0.9, 1.5) 1.4 (1.1, 1.6) 1.5 (0.6, 3.0) NS
1.4 (1.1, 1.7) 1.5 (1.2, 1.9) 1.4 (0.4, 3.0)
*

geometric means (95% C.I.);

arithmetic means (95% C.I.)

a

significantly different from Baseline, p<0.005

b

significantly different from 6 Months, p<0.005

c

significantly different from 12 Months, p<0.005